154 related articles for article (PubMed ID: 38128940)
21. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy.
Green DA; Rink M; Hansen J; Cha EK; Robinson B; Tian Z; Chun FK; Tagawa S; Karakiewicz PI; Fisch M; Scherr DS; Shariat SF
BJU Int; 2013 Mar; 111(3):404-11. PubMed ID: 22805163
[TBL] [Abstract][Full Text] [Related]
22. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
[TBL] [Abstract][Full Text] [Related]
23. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.
van den Bosch S; Alfred Witjes J
Eur Urol; 2011 Sep; 60(3):493-500. PubMed ID: 21664041
[TBL] [Abstract][Full Text] [Related]
24. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
Hinsenveld FJ; Boormans JL; van der Poel HG; van der Schoot DKE; Vis AN; Aben KKH; Arends TJ; Ausems PJ; Baselmans D; Berger C; Berrens A; Bickerstaffe H; Bos SD; Braam M; Buddingh KT; Claus S; Dekker K; van Doeveren T; Einerhand S; Fossion L; van Gennep EJ; van Ginkel N; Palacios G; Hermans T; Hobijn MM; van Huystee SH; Jaspers-Valentijn M; Klaver OS; Koldewijn EL; Korsten L; Lenting A; Lentjes KJ; Luiting HB; van der Meer S; Nieuwenhuijzen JA; Noordzij MA; Nooter RI; Notenboom C; Oomen R; van Roermund J; de Rooij J; Roshani H; Schrier BP; van der Slot MA; Somford DM; Stelwagen PJ; Stroux A; van der West A; Wijsman BP; Windt W; van Zanten P; van Beek SC;
Urol Oncol; 2022 Feb; 40(2):60.e1-60.e9. PubMed ID: 34303597
[TBL] [Abstract][Full Text] [Related]
25. Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications.
Haas M; Knobloch C; Mayr R; Gierth M; Pickl C; Engelmann S; Denzinger S; Burger M; Breyer J; Holbach S
Urol Int; 2023; 107(3):246-256. PubMed ID: 36693329
[TBL] [Abstract][Full Text] [Related]
26. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
28. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
29. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
30. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
[TBL] [Abstract][Full Text] [Related]
31. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
32. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
[TBL] [Abstract][Full Text] [Related]
33. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
34. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
35. [Radical cystectomy in patients with pathological non-muscle invasive bladder cancer].
Hao H; Su XH; Zheng W; Ge P; He Q; Shen Q; Yang XY; Zhang Z; Li XS; Lin J; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):627-631. PubMed ID: 29263502
[TBL] [Abstract][Full Text] [Related]
36. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
[TBL] [Abstract][Full Text] [Related]
37. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.
Zehnder P; Thalmann GN
Curr Opin Urol; 2013 Sep; 23(5):423-8. PubMed ID: 23880740
[TBL] [Abstract][Full Text] [Related]
38. Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.
Akitake M; Yamaguchi A; Shiota M; Imada K; Tatsugami K; Yokomizo A; Naito S; Eto M
Anticancer Res; 2019 Aug; 39(8):4325-4328. PubMed ID: 31366524
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
Kijima T; Tanaka H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
Clin Genitourin Cancer; 2020 Aug; 18(4):268-273.e2. PubMed ID: 31883941
[TBL] [Abstract][Full Text] [Related]
40. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
